Medication Use Among Children with Asthma in East Harlem
Overview
Affiliations
Purpose: To examine daily use of antiinflammatory medication among children with asthma in East Harlem, where hospitalization rates for asthma are among the highest in the United States.
Methods: We analyzed parent/guardian reports of medications used by children with current asthma (defined as physician diagnosis and wheezing during the previous 12 months) identified from a cross-sectional survey conducted in 2 elementary schools.
Results: From an overall sample of 1319 children, 298 with current asthma were included in this analysis. Most of those with asthma were Puerto Rican (136 [46%]) or black (98 [33%]), 168 (57%) were boys, and the median age was 8 years old. Overall, 65 (22%) were using antiinflammatory medication on a daily basis. A subgroup of 107 children with asthma had been hospitalized during the previous 12 months or had used beta(2)-agonist on a daily basis, suggesting persistent or severe asthma. Of these 107 children, 42 (39%) were taking antiinflammatory medication on a daily basis. Multivariate analysis of these 107 children revealed that daily use of antiinflammatory medication was associated with using a spacer tube (adjusted odds ratio [AOR]: 3. 08; 95% confidence interval [CI]: 1.27,7.47) and having seen a physician in the past 6 months (AOR: 3.46; CI: 1.01,11.9). Compared with Puerto Ricans, blacks (AOR:.32; CI:.12,.89) or children of other races/ethnicities (AOR:.27; CI:.09,.85) were less likely to use antiinflammatory medication on a daily basis.
Conclusion: Daily use of antiinflammatory medication for children with persistent or severe asthma in East Harlem was underused. Differences in access to care may explain some findings; however, reasons for ethnic differences in use remain unclear. Both community interventions and additional provider education are needed.
Holmes L, Orom H, Lehman H, Lampkin S, Halterman J, Akiki V J Asthma. 2020; 59(3):523-535.
PMID: 33322963 PMC: 8281495. DOI: 10.1080/02770903.2020.1864823.
Halterman J, Riekert K, Fagnano M, Tremblay P, Blaakman S, Tajon R J Asthma. 2020; 59(3):494-506.
PMID: 33307900 PMC: 8285039. DOI: 10.1080/02770903.2020.1856869.
Akintobi T, Jacobs T, Sabbs D, Holden K, Braithwaite R, Johnson L Prev Chronic Dis. 2020; 17:E83.
PMID: 32790605 PMC: 7458103. DOI: 10.5888/pcd17.200255.
Hull S, McKibben S, Homer K, Taylor S, Pike K, Griffiths C NPJ Prim Care Respir Med. 2016; 26:16049.
PMID: 27537194 PMC: 4989925. DOI: 10.1038/npjpcrm.2016.49.
Factors associated with high short-acting β2-agonist use in urban children with asthma.
Butz A, Ogborn J, Mudd S, Ballreich J, Tsoukleris M, Kub J Ann Allergy Asthma Immunol. 2015; 114(5):385-92.
PMID: 25840499 PMC: 4426068. DOI: 10.1016/j.anai.2015.03.002.